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INTRODUCTION 
  Myocardial Infarction generally occurs with the abrupt decrease in 
coronary blood flow that follows a thrombotic occlusion of a coronary artery 
previously narrowed by atherosclerosis. The injury is produced by or facilitated 
by factors such as cigarette smoking, hypertension, lipid accumulation, Diabetes 
and a number of other factors. 
 A quote from Berkeley heart lab - "Just being an Indian descent puts you 
at a high risk of coronary artery disease". The pattern of coronary artery disease 
is indeed changing in India. 
It has been reported to be as follows: 
a) Coronary artery disease appears a decade earlier in India than    other 
countries. 
b) Males are affected more than females 
c) Heavy smoking is an important contributing factor 
d) Hypertension and Diabetes account for about 40 percent of all cases. 
 The above findings were based on a clinical study done in Chandigarh in 
Persons of age greater than 30. 
 The risk of coronary artery disease in Indians is 3-4 times higher than 
white Americans, 6 times higher than Chinese and 20 times higher than 
Japanese Enas EA, Grag A, Davidson NA1 et al - coronary artery disease risk 
factors in first generation immigrant Asian Indians to the USA). 
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 Indians are prone as a community to coronary artery disease at a much 
younger age. The disease pattern is severe and diffuse. Premature coronary 
artery disease is defined as coronary artery disease occurring before the age of 
40 years. Indians are affected by coronary artery disease 5-10 years earlier than 
the other communities and also they show higher incidence of hospitalization, 
morbidity, and mortality than other ethnic groups. The above data is based on a 
study by EnasEA, Dhawan J, Petkar S et al.2 coronary artery disease in Asia 
Cigarette smoking has been the single factor very strongly associated with CAD 
in the young adult3, Perhaps of equal interest is the lack of a strong association 
of other traditional risk factors to CAD in the young. Hypertension and lack of 
exercise are both firmly established risk factors for CAD in general. 
Observations in approximately 80 clinical and epidemiological studies 
suggested that elevated tHcy is a risk factor for atherosclerotic vascular disease 
and for arterial and venous thromboembolism.    The aim of the present study is 
to evaluate the role of Hyperhomocysteine as a predictor of MI in young South 
Indian patient. 
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REVIEW OF LITERATURE 
 
 Myocardial infarction generally occurs with the abrupt decrease in 
Coronary blood flow that follows a thrombotic occlusion of a coronary artery 
previously narrowed by atherosclerosis. 
NARY ATHEROSCLEROSIS 
 The earliest lesions of atherosclerosis can be found in young children and 
infants in the form of fatty streak whereas the advanced lesion, the fibrous 
plaques, generally appears during early adulthood and progress with age4.The 
abdominal aorta is involved earliest. The aorta is usually most heavily involved 
at or near the orifice of its branches (particularly at the level of coronary 
arteries)4. In coronary arteries, raised lesions are most prominent in the main 
stems, the highest incidence being a short distance beyond the ostia. 
Atherosclerosis is usually always found in the epicardial (extramural) portions 
of the vessels, while the intramural coronary arteries are spared, coronary 
atherosclerosis is often diffuse. The degree to which the lumen is narrowed 
varies, but once the process has commenced, all the intima of the extramural 
portions of the vessels are usually involved. Typical atheromatous fibrous 
plaques also develop in saphenous vein, which is used for aortocoronaryby pass 
graft. 
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HYPOTHESES OF ATHEROSCLEROSIS 
The response to Injury Hypothesis 
           The endothelial lining cells are exposed to repeated or continuous insults. 
Dysfunctional endothelial cells at the susceptible sites in the arterial tree would 
lead to exposure of the subendothelial tissue to increased concentrations of 
plasma constituents. This triggers a sequence of events including monocytes and 
platelet adherence, migration, platelet aggregation and formation of 
microthrombi and release of secretory products. This causes proliferation of 
smooth muscle cells at these sites of injury. Monocytes become transformed to 
foam cells. Thus a well developed plaque is formed5 
Monoclonal Hypothesis 
 This states that the intimal proliferative lesion results from the 
multiplication of single, individual smooth muscle cells, as do benign tumors. 
According to this hypothesis, the intimal smooth muscle cell that proliferate to 
form an atheroma are normally under feedback control by mitosis inhibitors 
formed by the smooth muscle cells in the contiguous media, and this feedback 
control system tends to fail with age as these controlling cells die and are not 
adequately replaced6. 
RISK FACTORS 
 A number of factors are present more frequently in individuals who 
develop atherosclerosis much earlier than in general population and these 
factors have been termed as risk factors. 
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          The risk factor concept implies that a person with at least one risk factor 
is more likely to develop a clinical atherosclerotic event and is likely to do so 
earlier than a person with no risk factors. The presence of multiple risk factors 
further accelerates atherosclerosis. 
 Hypercholesterolemia, hypertension and cigarette smoking may be the 
most potent factors for atherosclerosis7. Risk factors also vary in terms of their 
potential reversibility with current techniques of preventive management. 
 The 27th Bethesda conferences, conducted by the American College of 
Cardiology placed the risk factors into four categories. Modification of which 
will lower the incidence of coronary artery disease.  
These categories are as follows: 
 CATEGORY I 
 CATEGORY II 
 CATEGORY  III 
 CATEGORY IV 
CATEGORY I 
¾ Basic research and human observational study indicate a clear causal 
relationship. 
¾ Intervention data demonstrates the magnitude of the benefit and risk. 
¾ Interventions are cost-effective and have been proved to lower coronary 
artery disease risk. 
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 1. Cigarette Smoking 
 2. LDL Cholesterol 
 3. High fat / high cholesterol diet 
 4. Hypertension 
 5. Left Ventricular Hypertrophy 
CATEGORY II 
> Studies indicate a causal relationship. 
> Intervention data for large scale trials are limited. 
> Cost effectiveness not ascertained but likely to lower coronary artery disease 
1. Diabetes Mellitus 
2. Physical inactivity 
3. HDL Cholesterol 
4. Triglycerides, LDL cholesterol 
5. Obesity 
6. Post menopausal status 
CATEGORY III 
> Studies indicate association 
> Interventions have not been tested adequately 
> Might lower risk 
1. Psychosocial factors 
2. Lipoprotein (a) 
3. Homocysteine 
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4. Oxidative stress 
5. No alcohol consumption 
CATEGORY IV 
> Factors associated with coronary artery disease risk, but cannot be modified. 
1. Age 
2. Male gender 
3. Low socio economic status 
4. Family history of early onset of coronary artery disease 
HOMOCYSTEINE 
 Homocysteine is a non-protein amino acid with the formula 
HSCH2CH2CH(NH2)CO2H. It is a homologue of the amino acid cysteine, 
differing by an additional methylene (-CH2-) group. It is biosynthesized 
from methionine by the removal of its terminal Cε methyl group. Homocysteine 
can be recycled into methionine or converted into cysteine with the aid of B-
vitamins. 
 While detection of high levels of homocysteine has been linked to 
cardiovascular disease, lowering homocysteinelevels may not improve 
outcomes8 
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Other reactions of biochemical significance 
 Homocysteine can cyclize to give homocysteinethiolactone, a five-
membered heterocycle. Because of this "self-looping" reaction, homocysteine-
containing peptides tend to cleave themselves 
Elevated homocysteine 
 Deficiencies of the vitamins folic acid (B9), pyridoxine (B6), 
or B12 (cobalamin) can lead to high homocysteine levels.12Supplementation with 
pyridoxine, folic acid, B12 or trimethylglycine (betaine) reduces the 
concentration of homocysteine in the bloodstream.1314Increased levels of 
homocysteine are linked to high concentrations of endothelial asymmetric 
dimethylarginine. Recent research suggests that intense, long duration exercise 
raises plasma homocysteine levels, perhaps by increasing the load on 
methionine metabolism.15Chronic consumption of alcohol may also result in 
increased plasma levels of homocysteine.1617 
 Elevations of homocysteine also occur in the 
rare hereditary disease homocystinuria and in the methylene-tetrahydrofolate-
reductase polymorphism genetic traits. The latter is quite common (about 10% 
of the world population) and it is linked to an increased incidence 
of thrombosis and cardiovascular disease, which occurs more often in people 
with above minimal levels of homocysteine (about 6 μmol/L). These individuals 
require adequate dietary riboflavin in order for homocysteine levels to remain 
normal. Common levels in Western populations are 10 to 12 and levels of 20 
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μmol/L are found in populations with low B-vitamin intakes (e.g., New Delhi) 
or in the older elderly (e.g., Rotterdam, Framingham). Women have 10-15% 
less homocysteine during their reproductive decades than men, which may help 
explain the fact they suffer myocardial infarction (heart attacks) on average 10 
to 15 years later than men. However, this phenomenon is more readily 
explained by higher levels of estrogen, which exerts a cardioprotective effect. 
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Blood reference ranges for homocysteine: 
Sex Age 
Lower 
limit 
Upper 
limit 
Unit Elevated 
Therapeutic 
target  
Female 
12–19 
years 
3.3[11] 7.2[11] μmol/L
> 10.4 
μmol/L 
or 
> 140 μg/dl
< 6.3 μmol/L[12]
or 
< 85 μg/dL[12] 
45[13] 100[13] μg/dL
 
>60 
years 
4.9[11] 11.6[11] μmol/L
 
 
66[13] 160[13] μg/dL
Male 
12–19 
years 
4.3[11] 9.9[11] μmol/L > 11.4 
μmol/L 
or 
> 150 μg/Dl
60[13] 130[13] μg/dL 
>60 
years 
5.9[11] 15.3[11] μmol/L
80[13] 210[13] μg/dL 
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Cardiovascular risks and related medical studies 
 A high level of blood serum homocysteine "Homocystinemia" is a 
powerful risk factor for cardiovascular disease. However, one study which 
attempted to decrease the risk by lowering homocysteine was not fruitful.18This 
study was conducted on nearly 5000 Norwegian heart attack survivors who 
already had severe, late-stage heart disease. No study has yet been conducted in 
a preventive capacity on subjects who are in a relatively good state of health. 
However, Dr. Kilmer McCully has shown in several research studies that the 
development of arteriosclerosis requires elevated levels of homocysteine in the 
blood. 
 Studies reported in 2006 have shown that giving vitamins [folic acid, 
B6 and B12] to reduce homocysteine levels may not quickly offer benefit, 
however a significant 25% reduction in stroke was found in the HOPE-2 
study .19 even in patients mostly with existing serious arterial decline although 
the overall death rate was not significantly changed by the intervention in the 
trial. Clearly, reducing homocysteine does not quickly repair existing structural 
damage of the artery architecture. However, the science is strongly supporting 
the biochemistry that homocysteine degrades and inhibits the formation of the 
three main structural components of the artery, collagen, elastin and 
the proteoglycans. Homocysteine permanently degrades cysteine disulfide 
bridges and lysine amino acid residues in proteins, gradually affecting function 
and structure. Simply put, homocysteine is a 'corrosive' of long-living proteins, 
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i.e., collagen or elastin, or life-long proteins, i.e., fibrillin. These long-term 
effects are difficult to establish in clinical trials focusing on groups with existing 
artery decline. The main role of reducing homocysteine is possibly in 
'prevention' but studies in patients with pre-existing conditions found no 
significant benefit nor damage. 19, 20, 21Hypotheses have been offered to address 
the failure of homocysteine-lowering therapies to reduce cardiovascular event 
frequency.22One suggestion is that folic acid may directly cause an increased 
build-up of arterial plaque, independent of its homocysteine-lowering effects. 
Alternatively, folic acid and vitamin B12 may cause an overall change in gene 
methylation levels in vascular cells, which may also promote plaque growth. 
Finally, altering methlyation activity in cells might increase methylation of l-
arginine to asymmetric dimethylarginine which can increase the risk of vascular 
disease. Thus alternative homocysteine-lowering therapies may yet be 
developed which show greater effects on development and progression of 
cardiovascular disease. 
 The VITATOPS trial (results presented in May 2010 by the lead 
investigator, Dr Graeme J Hankey of Royal Perth Hospital, Australia at the 
European Stroke Conference 2010, in Barcelona, Spain) has concluded that B-
vitamin supplements, within 2 years, do not seem to significantly reduce 
subsequent stroke, MI, or vascular death in patients with a history of recent 
stroke and ischemic attack, despite lowering of homocysteine levels.23 
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Alzheimer's disease and homocysteine 
 Studies demonstrate the connection between elevated levels of 
homocysteine (hyperhomocysteinaemia) and occurrence of Alzheimer's disease 
(AD) besides other cognitive impairments. Researchers suggest that B-group-
vitamin supplementation (including folate) may possibly decrease chances to 
develop AD.24, 25, 26 
Bone weakness and breaks 
 Elevated levels of homocysteine have been linked to 
increased fractures in elderly persons. The high level of homocysteine will auto-
oxidize and react with reactive oxygen intermediates and damage endothelial 
cells and has a higher risk to form a thrombus.27, 28 Homocysteine does not affect 
bone density. Instead, it appears that homocysteine affects collagen by 
interfering with the cross-linking between the collagen fibers and the tissues 
they reinforce. Whereas the HOPE-2 trial20 showed a reduction in stroke 
incidence, in those with stroke there is a high rate of hip fractures in the affected 
side. A trial with 2 homocysteine-lowering vitamins (folate and B12) in people 
with prior stroke, there was an 80% reduction in fractures, mainly hip, after 2 
years. Interestingly, also here, bone density (and the number of falls) were 
identical in the vitamin and the placebo groups.29 
 Vitamin supplements counter the deleterious effects of homocysteine on 
collagen. As they inefficiently absorb B12 from food, elderly persons may 
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benefit from taking higher doses orally such as 100 mcg/day (found in some 
multivitamins) or by intramuscular injection 
Life style factor which increase Homocysteine levels include 
a. Diet - A low diet with deficiency of nutrients particularly B-6,  B-12, and 
folic acid. 
b. Smoking 
c. Alcohol - high alcohol intake reduce the absorption of vitamins. 
d. Lack of physical exercise and excessive stress. 
e. Obesity. 
f. Drugs such as Oral contraceptive pills, L-Dopa, Methotrexate, Nicotinic 
acid, Theophylline, etc. 
Renal failure, hypothyroidism, psoriasis and malignancies. 
HYPERHOMOCYSTENEMIA AND VASCULAR PROBLEMS: 
Hyperhomocysteinemia or hyperhomocysteinaemia is a medical condition 
characterized by an abnormally large level of homocysteinein the blood. 
 As a consequence of the biochemical reactions in which homocysteine is 
involved, deficiencies of the vitamins pyridoxine (B6), folic acid(B9), or B12 can 
lead to high homocysteinelevels.30 Supplementation with pyridoxine, folic acid, 
B12, or trimethylglycine (betaine) reduces the concentration of homocysteine in 
the bloodstream31. Hyperhomocysteinemia is a disease which increases risk of 
other artery or vein diseases. 
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 Hyperhomocysteinemia usually occurs in people with at least one 
defective gene, which affects the breakdown of homocysteine. There are two 
common gene defects in the population. The first gene codes for an enzyme. 
This gene is known as methylenetetrahydrofolatereductase or MTHFR. The 
second common defective gene is methioninesynthetase or MS.  
 Hyperhomocysteinemia is a high level of homocysteine in human blood. 
A high level of homocysteine makes a person more prone to endothelial injury, 
which leads to vascular inflammation, which in turn may lead to atherogenesis 
and thrombophilic situation which can result in ischemic injury.32 
Hyperhomocysteinemia is therefore a risk factor for coronary artery disease. 
Coronary artery disease is when an atherosclerosis leads to occlusion of the 
lumina of the coronary arteries. These arteries supply the heart with oxygenated 
blood. 
 People who are most likely to get hyperhomocysteinemia are with two 
defective genes and having a diet low in folate and vitamin B6 and B12. The 
effect upon these people is greater than the people with only one defective gene.  
Hyperhomocysteinemia is linked to an increased risk of blood clots, heart 
attacks and strokes. It can cause miscarriage, pre-eclampsia and other birth 
defects in pregnant women. 
 The best way to prevent hyperhomocysteinemia is to eat foods which 
contain B6, B12, and folate such as potato, greens, beans and fish. The only 
natural sources of B12 are from animal products. 
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 However, it is difficult to show that reducing your homocysteine levels 
will improve your health. In a study designed to see if lowering homocysteine 
will reduce heart ("vascular") and kidney problems, the results were just the 
opposite.33 Patients with diabetes and known kidney disease ("diabetic 
nephropathy") were given commonly used doses of B vitamins: folic 
acid (2.5 mg/d), vitamin B6 (25 mg/d), and vitamin B12 (1 mg/d). Diabetics 
usually have elevated homocysteine levels and a higher risk for heart attacks 
and strokes, so they make an ideal population to study homocysteine's effects on 
human health. Taking B vitamins did reduce homocysteine, as expected, but 
unfortunately doubled the patient's risk of serious vascular complications (heart 
attack, stroke, death) and worsened their kidney function. 
MANAGEMENT OF HYPERHOMOCYSTEINEMIA 
Genetic counseling in case of congenital disorders. 
 Once elevated Homocysteine has been diagnosed, the next step is a 
simple examination of diet. A healthy balanced diet containing at least five 
servings of fruits and vegetables a day will help to lower the Homocysteine 
level and keep within the ideal range. 
 Folic acid and vitamins B-6 and B-12 have been shown to have the 
greatest effect at breaking down harmful Homocysteine from within the body34. 
Foods rich in folic acid include: 
a. Green leafy vegetables such as spinach, cabbage, etc. 
b. Citrus fruits particularly orange and grape fruits. 
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c. Pulses such as black-eyed beans and chick peas. 
d. Whole grain cereals. 
 Maintaining low plasma Homocysteine is also easily achieved through 
vitamin supplementation. Patients with elevated Homocysteine (> 14 u mol/L 
with no other risk factors, or > 11 u mol/L for patients with more than 2 risk 
factors) can be treated effectively with multivitamins containing 400 u g of folic 
acid supplemented with an additional 400 to 1000 u g of folic acid. After 6 to 8 
weeks of vitamin supplementation, Homocysteine should be repeated. 
Continued elevated Homocysteine should be treated with increased doses of 
supplemental folic acid up to 5mg/d.35 For many people, the daily intake of 500 
u g TMG (Trimethyl glycine), 800 u g of folic acid, 1000 u g of vitamin B12 and 
250 mg of choline, 250 mg of inositol, 30mg of zinc and 100mg of vitamin B6 
will keep Homocysteine levels in the normal range.. 
CORONARY ARTERY DISEASE AND OTHER RISK   FACTORS 
 The major conventional coronary risk factors are smoking, hypertension, 
sedentary life style, high LDL cholesterol heredofamilial factors and diabetes 
mellitus. The newer coronary risk factors are lipoprotein (a), psychosocial 
stress, etc. 
 A cohort, prospective study on coronary artery disease in the young; Here 
do familial or faulty life style or both was done in India. The study comprised 
70 young (< 40 years) CAD patients. There were 56 males and 14 females, 
mostly belonging to 36-40 age groups. More than half of the patients were from 
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low socioeconomic group. It was found that 61.42% were chronic smokers and 
all of them were males. 18.8% gave history of CAD in their first degree 
relatives. Hypertension was detected in 51.42% cases, obesity in 35.71% cases 
and underweight in 14% subjects. Hypercholesterolemia was observed in 
41.66% cases. Low HDL was the next most common dylipidemia. 7.14%cases 
were diabetic. Most ominous combination was smoking, low socioeconomic 
status, increased waist-hip ratio (WHR), dyslipidemia and hypertension. The 
study reported that both heredofamilial as well as faulty life style risk factors 
contribute to the development of CAD in young people.36 
 A case control study to assess the association of lipoprotein (a) [(Lp (a)] 
with CAD was conducted in Andhra Pradesh. 151 consecutive patients with 
clinical and angiographic evidence of CAD and 49 healthy controls were drawn 
for the study. Triglycerides, VLDL-C, total-cholesterol/high density cholesterol 
(HDL-C) ratio, low density cholesterol (LDL-C)/HDL-C ratio, and Lp (a) were 
found to be higher in pati In female sex and in those with family h/o CAD, 
higher total and LDL cholesterol levels were observed to be associated with 
higher Lp (a) levels. Significant difference in Lp(a) levels were observed 
between normal coronaries Vs single and triple vessel disease and also between 
single vs double and triple vessel disease. The findings suggested that a cut-off 
level of 25mg/dl for the determination of risk of CAD.37 
 A case-control study to determine the relationship between plasma 
lipoprotein (a) levels and their phenotypes in a group of South Indian patients 
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with coronary artery disease was done in CMC, Vellore. A total of 104 patients 
with angiographically proven coronary artery disease were compared with 104 
age and sex-matched controls with no risk factors. Lipoprotein (a) levels were 
measured by ELISA method and its phenotyping was done by SDS agarose gel 
electrophoresis. Plasma lipoprotein (a) levels were significantly elevated in 
patients with coronary artery disease as compared to controls Lipoprotein (a) 
phenotyping showed that low-molecular weight isoforms were found only in 
19.2% of the patients with coronary artery disease and their plasma lipoprotein 
(a) levels were significantly elevated compared to ents than controls. 
 CAD patients with higher molecular weight isoforms. It was concluded 
that plasma lipoprotein (a) levels are significantly elevated in CAD patients and 
the commoner phenotype in a south Indian population is the larger 
apolipoprotein (a) in which the lipoprotein (a) levels are lower.38 
 A case-control study on the comparative account of serum lipids, 
lipoproteins and Apolipoprotein-B in patients of coronary artery disease was 
done in Punjab. Serum total lipids (cholesterol and triglycerides), lipoproteins 
(VLDL, LDL and HDL) and Apolipoprotein-B levels of normal healthy 
individuals (n=25) and coronary artery disease patients (n=25) were estimated. 
  The objective of the present study was to ascertain the role of apo-B in 
causation and inheritance of CAD. It was observed that on an average serum 
total cholesterol and triglyceride more than 200mg/dl bring the individuals to a 
risk of CAD irrespective of the age. CAD patients achieved this value at an 
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early age (35-45 years). Similarly VLDL and LDL levels were found to be 
raised and HDL levels were found to be lower in CAD patients compared to 
age-matched controls. Serum apo-B levels were significantly raised in CAD 
patients and patient with positive family history of CAD. A positive coefficient 
of correlation was between serum apo-B and LDL levels suggesting that more 
the number of Apo-B particles, more will be the synthesis of atherogenic 
particles (LDL). The study concluded that elevated apo-B levels turn out to be a 
genetic factor responsible for causative factor of coronary artery disease.39 
 A prospective, case-cross over study was done in Israel on negative 
emotions, anger and sudden changes in posture as independent triggers for 
ischemic stroke. 200 consecutive patients hospitalized with an ischemic stroke 
or a transient ischemic attack were interviewed one to four days after stroke 
onset using a validated questionnaire. Reported exposure to potential triggers, 
such as negative and positive emotions, anger, sudden postural changes in 
response to a starting event, strenuous physical exertion, heavy eating and 
sudden temperature changes during a two-hour period prior to stroke onset were 
compared with the same period during the preceding day and to average 
exposures in the previous year. Anger and other negative emotions were rated 
on a seven-point scale and were said to be present if the score was 5 or higher. 
During 2 hours before stroke 76 patients experienced at least one of the study 
triggers. Thus the study demonstrated that apart from the conventional risk 
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factors, there are factors that may trigger the premature onset of stroke and this 
is an important area of potential invention. 
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AIM OF STUDY 
 
The aim of the present study is 
> to estimate the plasma Homocysteine levels in young patients presenting with 
myocardial infarction 
> to assess the possible role of Homocysteine as non-traditional risk factor in 
these patients 
> to study the association of Homocysteine with traditional risk factors. 
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STUDY PLAN 
 The present study was planned to estimate the plasma Homocysteine in 
young patients presenting with MI, and to associate with Homocysteine with 
non-traditional risk factor and finally to assess the role of Homocysteine as a 
new predictor of MI in young patients with signs of myocardial infarction, 
admitted in the Tirunelveli medical college as outlined below : 
> Selection of patients based on inclusion criteria. 
> Study of demographic and disease presenting characteristics and correlation 
with MI. 
> Collect patient family history and family medication history and to associate 
with the diagnosed indications. 
> Estimation of Homocysteine levels in MI patients and compare it with 
healthy subjects. 
> To study the association of Homocysteine and disease. 
To explore the possible influence of Homocysteine on traditional risk factors. 
 
 
 
 
 
 
 
26 
 
MATERIALS AND METHODS 
Setting 
 Department of Medicine and Department of Cardiology, Tirunelveli 
medical collegehospital,Tirunelveli. 
Study design 
 This is a cross-sectional, Case control study carried out in young MI 
patients. 
Study protocol 
 Patients admitted in Intensive Care Unit of Tirunelveli medical college 
hospital for MI were enrolled in the study. Patients were interviewed and a 
designed questionnaire was used to collect demographic details, previous 
history of MI, presenting symptoms, the earlier medication and food 
supplementation used. 
Ethical Committee Approval 
 The study protocol was duly approved by the Ethics Committee of 
Tirunelveli medical college hospital. 
Collaborating Department 
1. Department of Medicine and Department of Cardiology,Tirunelveli 
 medical college hospital. 
2. Path care lab Tirunelveli. 
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Study Criteria 
Selection of patients: Inclusion Criteria: 
 The following categories of patients from cardiology department are 
included in the study. 
> Inpatients admitted for myocardial infarction. 
> Patients with age 45 years and below only. 
Exclusion criteria: 
> Patients with age above 45 years. 
> Patients suffering from diseases such as renal failure, hypothyroidism, 
 psoriasis, any malignancies and psychiatric disorders. 
> Patients taking drugs such as Methotrexate, oral contraceptive pills, L-
 dopa, nicotinic acid and Theophylline. 
> Patients taking folic acid or any vitamin supplement. 
SOURCE OF DATA 
 Department of Cardiology, Tirunelveli medical college hospital. The data 
were obtained from 
> Patient interview 
> Treatment chart 
> Prescriptions 
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METHOD OF COLLECTION OF DATA 
 This is a cross-sectional, case control study carried out from Dec 2010 to 
Dec 2011, to analyze the Homocysteine levels in young MI patients and its 
association with other risk factors. 
 Proforma was prepared as an aid for collecting the demographic data. 
Model of Proforma is given in Appendix. 
ESTIMATION OF HOMOCYSTEINE 
 Estimation of Homocysteine was performed by automated immuno assay 
analyzer - IMX ABBOTT System (USA). 
DATA ANALYSIS: 
 Graph-Pad software was used for statistical analysis. 
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2. AGE DISTRIBUTION 
Age in 
years 
Case Control 
N % N % 
30-34 7 17.5 4 16.0 
35-39 19 47.5 12 48.0 
40-44 14 35.0 9 36.0 
Total 40 100.0 25 100.0 
           χ2 =0.026 f =2  p=0.967 
Fig 2 
 
 In our study group major portion of patients are in age group 35-39 
yrs(47.5%) and there is no significance regarding age on comparing cases and 
control(p=0.967). 
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Fig 3 
     In our study group smokers and diabetics occupy the major proportion. 
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Fig 4 
 
BMI 
case Control 
N % N % 
Under weight 1 2.5 0 .0 
Normal 23 57.5 8 32.0 
Over weight 11 27.5 11 44.0 
Obese 5 12.5 6 24.0 
Total 40 100.0 25 100.0 
      χ2 =5.162 df =3  p=0.160 
 In our study group major portion of our patients are in normal BMI (57.5%)and 
there is no significance on comparing cases and controls(p=0.160). 
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Fig. 6 
 
Alcoholism 
case Control 
N % N % 
Yes 13 32.5 3 12.0 
No 27 67.5 22 88.0 
Total 40 100.0 25 100.0 
             χ2 =3.484 df =1  p=0.062 
 
 In our study group major portion of our cases alchoholics(32.5%). There 
is no significance on comparing the cases and control(p=0.062). 
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6.COMPARISON OF ALCHOHOLISM IN STUDY 
GROUP 
Alchoholics
Non‐alchoholic
35 
 
 
 
 
7. COMPARISON OF FAMILY HISTORY OF MI IN STUDY GROUP 
 
FH 
case Control 
N % N % 
Yes 7 17.5 1 4.0 
No 33 82.5 24 96.0 
Total 40 100.0 25 100.0 
            χ2 =2.598 df =1  p=0.107 
 
 
 In our study group there is no significant association on comparing the 
family history of MI between cases and controls. 
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8. COMPARISON OF PAST HISTORY OF MI IN STUDY GROUP 
 
 
PH 
case Control 
N % N % 
Yes 7 17.5 0 .0 
No 33 82.5 25 100.0 
Total 40 100.0 25 100.0 
             χ2 =4.903 df =1  p=0.027 
  
 
 In our study group there is no significant association on comparing the 
past history of MI between cases and controls. 
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9. COMPARISON OF HYPERTENSION IN STUDY GROUP 
 
 
HT 
case Control 
N % N % 
Yes 12 30.0 2 8.0 
No 28 70.0 23 92.0 
Total 40 100.0 25 100.0 
            χ2 =4.406 df =1  p=0.036 
 
 
 In our study group there is significance on comparing hypertension 
between cases and controls(p=0.036). 
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10. COMPARISON OF DIABETES IN STUDY GROUP 
 
 
DM 
case Control 
N % N % 
Yes 15 37.5 5 20.0 
No 25 62.5 20 80.0 
Total 40 100.0 25 100.0 
             χ2 =2.212 df =1  p=0137 
 
 
 In our study group there is no significance on comparing diabetes 
between cases and controls. 
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11.COMPARISON OF TOTAL CHOLESTEROL IN STUDY GROUP 
 
TC 
case Control 
N % N % 
>200 4 10.0 0 .0 
<200 36 90.0 25 100.0 
Total 40 100.0 25 100.0 
            χ2 =2.664 df =1  p=0.103 
 
 
12.COMPARISON OF LDL IN STUDY GROUP 
LDL 
case Control 
N % N % 
>100 4 10.0 0 .0 
<100 36 90.0 25 100.0 
Total 40 100.0 25 100.0 
             χ2 =2.664 df =1  p=0103 
 
 In our study group there is no significance on comparing Total 
cholesterol and LDL between cases and controls. 
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13.COMPARISON OF HDL IN STUDY GROUP 
 
 
HDL 
case Control 
N % N % 
Abnormal 38 95.0 22 88.0 
Normal 2 5.0 3 12.0 
Total 40 100.0 25 100.0 
             χ2 =1.062 df =1  p=0.303 
 
 
 In our study group there is no significance on comparing HDL between 
cases and controls. 
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14. COMPARISON OF TGL IN STUDY GROUP 
 
 
TGL 
case Control 
N % N % 
>150 15 37.5 2 8.0 
<150 25 62.5 23 92.0 
Total 40 100.0 25 100.0 
            χ2 =6.932 df =1  p=0.008 
 
 
 In our study group there is significance on comparing TGL  between 
cases and controls(p=0.008) 
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15.COMPARISON OF HOMOCYSTEINE IN STUDY GROUP 
 
 
Homocysteine 
Case Control 
N % N % 
<10 9 22.5 16 64.0 
10-15 15 37.5 9 36.0 
15-20 13 32.5 0 .0 
>20 3 7.5 0 .0 
Total 40 100.0 25 100.0 
             χ2 =16.898 df =3 p=0.001 
 
 
 In our study group major portion of cases having homocysteine more than 
15mc mol(40%). On comparing the homocysteine between cases and control 
there is significant association(p=0.001). 
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16.COMPARISON OF HOMOCYSTEINE WITH OTHER RISK 
FACTORS 
 
 N 
Homocysteine 
t P Mean Sd 
Sex Male 56 12.2 6.7
0.409 0.684Female 9 11.2 4.5
Smoking Yes 29 14.1 8.3 2.376 
 
0.021
No 36 10.4 3.8
ALCOHOL 
 
Yes 16 14.8 4.7 2.007 
 
0.049
No 49 11.1 6.7
FH 
 
Yes 8 17.2 14.0 2.516 
 
0.014
No 57 11.3 4.3
PH 
 
Yes 7 12.4 4.6 0.152 
 
0.880
No 58 12.0 6.7
HT 
 
Yes 14 11.3 3.9 -0.446 
 
0.657
No 51 12.2 7.0
DM 
 
Yes 20 11.9 4.1 -0.087 
 
0.931
No 45 12.1 7.3
TC 
 
>200 4 17.6 4.1 1.829 
 
0.072
<200 61 11.7 6.4
LDL 
>100 4 13.4 5.0
0.447 0.656<100 61 11.9 6.5
TGL 
>150 17 15.5 9.5
2.734 0.008<150 48 10.8 4.5
HDL 
Abnormal 60 12.2 6.6
0.662 0.510Normal 5 10.2 3.9
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 In our study on comparing the elevated homocysteine with other risk 
factors it shows significant relation with smokers(p=0.021), Family history of 
MI(p=0.014), Alchoholics(p=0.049) and elevated TGL levels(p=0.008) 
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DISCUSSION 
 Cardiovascular disease is a major global health problem reaching 
epidemic proportions in the Indian sub-continent accounting for 78% of all 
deaths. Higher risk of cardiovascular disease have been reported among south 
Asians regardless of whether they live overseas or in their native lands. 
Presence of conventional risk factors such as Smoking, diabetes mellitus, 
Hypertension, dyslipidemia are clearly associated with coronary artery disese.  
Prevalence of risk factors is higher and rapidly raising in Indian population. 
This predisposition to accelerated atherosclerosis seems to have genetic 
predisposition but is being enhanced by changing lifestyle, dietary and cultural 
preferences, and suboptimal application of health care. Even though the 
environmental and behavioral responses to urbanization and westernization 
appear to be consistent across cultures, the genetically determined metabolic 
response to these environmental changes and resulting CAD risk profiles may 
vary in different ethnic groups.42 The extent to which these variations in 
different ethnic groups are due to genetic or environmental factors remains 
unclear.43 
 According to the Indian studies, the prevalence rate of CAD was 9.7% in 
Delhi, 3.5% in Rajasthan and 11% in urban population of South India.44 
      Among all the ethnic groups studied, the standard mortality ratio for men 
born in the Indian subcontinent and aged between 20 and 69 years was by far 
the highest.45 
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      In the analysis by Balarajan, the excess mortality seen among immigrants 
from the subcontinent steadily increased with decreasing age. Men in the age 
group 20-29  and 30-39 years had SMRs of 313 and 210, respectively. The rate 
of first MI was five times higher among Indian men compared to the Europeans 
in the study.46 
 Further, the mean age at first MI was about 5 years lower for the Indian 
men (50.2 v 55.5 years). More South Asian patients (38% v. 22%) were found 
unsuitable for surgery because of extensive disease. CAD tends to occur earlier 
in life among people of Indian descent.47 
 In addition to the conventional risk factors such as smoking, HT, DM, 
hypercholesterolemia, obesity and reduced physical activity 
Hyperhomocysteinemia was found to be independent risk factor of CAD. 
 Identification of new markers such as homocysteine associated with an 
increased risk of CAD may provide a better insight into the pathology of 
coronary atherosclerosis and facilitate the development of preventive and 
therapeutic measures. 
 Normal values of plasma total homocysteine are between 5 and 15 u 
mol/L. In our study, the mean plasma homocysteine in healthy subjects was 
14.0 ± 7.4 and in CAD patients, the total plasma homocysteine was 8.8 ± 2.1 (P 
= 0.001) indicating that homocysteine level is an independent marker of CAD. 
A two fold increase in likelihood of MI among persons with a total Hcy 
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concentration more than or equal to 15 u mol/L has been noted in an United 
States study.49 
      An Indian study which gave a mean value of 22.81 ± 13.9 in cases and 
7.77 ± 7.3 in controls showed a significant difference of homocysteine values 
between the two groups and hence showed increased homocysteine levels 
among patients with coronary artery disease.50 
 However, another Indian study with a mean homocysteine value of four 
cases as 18.30 ± 10.08 u mol/L and control 18.04 ± 10.65 reported a negative 
association between homocysteine with MI.51 
Homocysteine and Smoking: 
 CAD patients who were smokers had a mean Hcy level of 14.1 ± 8.0 as 
compared to 10.4 ± 3.8 (p=0.021) in CAD patients who are non-smokers. This 
higher level of Hcy may be due to the influence of smoking in homocysteine 
metabolism. Among secondary causes of hyperhomocysteinemia, smoking 
plays an important role by interfering with the synthesis of pyridoxal phosphate, 
which is important for the conversion of homocysteine to cystathione by the 
enzyme cystathione b synthase.52 
Homocysteine and alcoholism: 
 Alcoholic intake interferes the absorption of vitamins and interferes with 
the metabolism of homocysteine, leading to hyperhomocysteinemia. In our 
study mean Hcy of alcoholics was found to be 14.8 ± 4.7 as compared to 11.1 ± 
6.7(p=0.049) in non-alcoholics. 
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Homocysteine and Hypertension: 
 A number of studies have shown a correlation between 
hyperhomocysteinemia and HT. However, a contradictory report was obtained 
from a western study with a mean value of tHcy 10.4 ± 53 in hypertensives.53 
 In my study also it shows that no significant co-relation between 
hyperhomocysteinemia and hypertensives(p=0.657). So further studies have to 
be conducted to establish relationship between hyperhomocysteinemia and 
hypertension. 
Homocysteine and Diabetes Mellitus: 
 Varied results were observed among diabetes as well. Munshi et al. 
demonstrated elevated homocysteine levels in non-insulin dependent diabetes 
subjects compared to age matched controls54 and Hoffman et al, reported that 
hyperhomocysteinemia is more common in type 1 diabetic patients with 
nephropathy.55 Deepa et al. did not reveal any significant increase in 
homocysteine level in diabetes with CAD.56 In our study population, there was a 
small difference in Hcy levels among diabetes and non diabetes patients (11.9 
and 12.1) 
Homocystiene and hypercholesterolaemia 
 In the Hordaland study in Norway, increasing plasma levels of 
cholesterol, triglycerides and smoking were associated with increasing levels of 
homocysteine. In our study, only 4 patients had hypercholesterolemia and there 
is no significant co-relation between hyperhomocysteine and 
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hypercholesterolemia(p=0.072). Lowered Hcy may be due to change in life 
style adopted by patients as part of treatment for high cholesterol. In addition 
majority of our patients were manual workers, not having sedentary life style 
pattern. 
               But in our study there is significant co-relation between 
hypertriglyceridemia and hyperhomocysteinemia(p=0.008). So further studies 
should be done to evaluate to co-relation between dyslipedemia and 
hyperhomocysteinemia. 
Homocysteine and Obesity: 
 In our study, 1.5% were underweight with Hcy value of 12.2, 47.7% 
normal body weight with Hcy value (12.2 ±8.6) and 33.8% over weight patients 
with (11.3 ± 3.5)Hcy, 16.9% obese patients having Hcy value (12.8 ± 4.2).  
Elevated levels of Hcy in under weight subjects could be due to malnutrition 
and its impaired effect on Hcy metabolism. 
Homocysteine and family history of CAD: 
 It is also interesting to note that Hcy levels were higher (17.2) in patients 
with a family history of MI in comparison of patients without such risk factor 
(Mean Hcy 11.3). 
Homocysteine and previous history of CAD: 
 Many studies have shown that patients with MI had significantly elevated 
tHcy levels compared to patients without such history as well as to controls.59  
However, in our study it was found that tHcy of patients with previous history 
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was lower that of patients with previous history of MI (12.4 Vs 12). 
 This may be due to the effects of administration of lipid lowering agents 
following the previous MI events. It has been reported in a study that lower 
levels of tHcy were observed amongst patients taking lipid-lowering agents.57 
Homocysteine and gender: 
 In this study, no significant difference was found in the total 
homocysteine levels of men and women (p=0.256). 
 The study matched with an Indian study where large number of women 
had high total homocysteine and were deficit in vitamin B12.58 
Hyperhomocysteinemia as a risk factor for MI may have profound public health 
implications because total homocysteine can be lowered inexpensively and 
easily by modification of dietary patterns and vitamin supplements. But a 
Western study had shown that vitamins did not reduce the risk of major 
cardiovascular events in patients with vascular disease.59 
 The results of ongoing clinical trials to determine the effect of 
multivitamin therapy on CAD are awaited. If casually related, our findings 
suggest that young people with high risk of MI may particularly benefit from 
interventions that lower total homocysteine concentrations. 
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CONCLUSION 
 At the threshold of this millennium, CAD is looming large as the new 
epidemic afflicting Indians at a relatively younger age. Of the 40 MI patients, 
24(60%) were having desirable plasma homocysteine levels (<15umol/L), 
16(24%) were having undesirable homocysteine levels (>15umol/L). 
 In the study, homocysteine was identified as a nontraditional risk factor 
for MI. Among the study population of MI significant proportion of patients 
were found to have higher homocysteine than control. In the study, the mean 
plasma homocysteine level in healthy subjects was 8.8 umol/l and in CAD 
patients the total plasma homocysteine was (14+7.4umol/l)(P=0.001) indicating 
that homocysteine level is an independent marker of CAD. 
 It was also found that homocysteine levels were higher in patients who 
had additional conventional risk factors when compared to patients without such 
risk factors except hypercholesterolemia. 
 However, as the study was limited to a small population due to financial 
constraint, analysis of a larger group would definitely give an insight into the 
various causative factors leading to hyperhomocysteinemia and its role in CAD 
among the young South Indian population. 
 As such Asian Indians are genetically predisposed to CAD. Hence it is 
mandatory to determine homocysteine levels in people after thirties so that 
preventive measures such as vitamin supplementation and life style 
modifications could be undertaken and thus reduce the incidence and mortality 
due to CAD. 
 PROFORMA 
 
Name of the patient :    Age : 
Marital Status :     Body Weight (in kg) : 
BMI :       Food habits : Veg: 
If non-veg, how frequently?    Sex: 
Height (in cms.):      Non-veg: 
SYMPTOMS: 
• Giddiness 
• Palpitation 
• Chest discomfort 
• Headache 
Habits :    a. Smoker 
If yes, how long? :  
Number of cigarettes/day :  
If discontinued, whether after MI: 
b. Alcoholic 
            If yes, how long? :  
Frequency (mild/moderate) :  
 If discontinued, whether after MI: 
Concomitant disease: 
Kidney failure: 
Psoriasis: 
Hypothyroidism: 
Diabetes Mellitus: 
Hypertension: 
CAD: 
 
 FAMILY HISTORY: 
Diabetes mellitus       : 
CAD         : 
HYPERTENSION : 
CKD         : 
Drug history 
a. Oral contraceptive pills: 
b.L-Dopa: 
c. Methotrexate: 
d.Nicotinic acid: 
e. Theophilline: 
f. Exposure to nitrous oxide: 
Any folic acid / vitamin being taken: 
General examination: 
g.Pallor 
h.Jaundice  
i. Pedal edema 
j. External markers of hyperlipidemia 
k.PR:  
l. BP: 
m.Systemic examination: CVS :  
n.      RS :  
o.      ABDOMEN: 
CNS : 
Diagnosis: 
Investigation: 
Haemoglobin%: 
ESR: 
Blood sugar: 
 Serum creatinine: 
Serum urea: 
Lipid profile: 
i. Total Cholesterol: 
ii. Triglycerides: 
iii.HDL: 
iv. VLDL: 
v. LDL: 
ECG 
ECHO: 
PLASMA HOMOCYSTIENE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MASTER CHART 
Cases 
S.  
No. Age Sex Smoking Alcohol FH PH HT DM BMI TC HDL LDL TGL HOMOC
1 33 M N Y N N Y N 18.1 149 42 103 160 12.2 
2 32 M Y Y N N Y N 23.6 153 43 85 182 13.1 
3 35 M Y N N N N N 22.5 165 44 74 175 11 
4 40 M Y Y N N N N 23.5 173 39 95 143 16.2 
5 36 M N N Y N N Y 24.4 185 38 75 180 12 
6 38 M Y Y N N N N 20.6 205 40 90 170 18.2 
7 40 M N N N N N N 21.8 172 38 83 191 16.3 
8 41 M Y N N N N Y 28.8 185 40 75 180 15.5 
9 42 F N N Y Y N Y 22.7 152 42 86 209 10 
10 43 M N N N N Y N 19.8 149 43 96 172 11 
11 39 M Y N Y N Y Y 18.8 163 40 69 123 12 
12 38 M Y N Y N N N 20.8 185 39 90 205 50.4 
13 39 M N Y N N N N 28.7 201 45 70 125 12 
14 35 M Y N N N N N 29.1 192 44 65 133 11 
15 43 M Y Y N Y N Y 25.6 230 41 103 145 18.3 
16 44 M N N N Y Y Y 20.6 171 39 64 130 13 
17 37 M Y N N N Y Y 21.6 163 40 72 141 14 
18 40 F N N N N N N 22.8 190 42 110 151 16.2 
19 41 M Y Y N N N Y 23.5 182 40 72 162 17 
20 43 M N N N N N N 24.8 153 39 106 110 7 
21 38 F N N N N N Y 19.6 149 38 98 120 6 
22 40 M Y N N N Y Y 19.4 142 40 68 131 15.8 
 23 39 M N Y N N N N 21.9 139 41 75 133 18 
24 44 M N N N Y N N 22.5 166 43 78 210 10 
25 43 M Y N Y Y N N 21.6 173 39 64 121 11 
26 38 M N N N N N N 23.3 149 38 80 123 19 
27 41 M Y Y Y N N Y 27.9 240 36 85 135 22 
28 36 M Y Y N N Y N 21.6 182 35 81 125 15.8 
29 37 M Y N N N N Y 23.6 171 40 63 141 11 
30 40 M N N N N N N 24 169 43 79 152 9 
31 42 M N N N N Y Y 22.3 135 41 71 115 5 
32 42 M Y N N Y N N 24.5 142 42 91 190 18.3 
33 33 M Y Y N N N N 20.9 165 37 85 113 19 
34 36 M N N N N Y Y 21.6 172 36 61 126 7 
35 35 M Y N N N N N 19.8 160 37 69 129 8 
36 40 F N N N N Y N 22.3 172 35 88 132 19.5 
37 41 M N Y Y N N Y 24.4 151 40 77 115 11 
38 32 M Y Y N N N N 20.6 141 40 90 117 20.5 
39 42 M N N N Y Y N 18.6 188 43 87 105 6 
40 39 M Y N N N N N 24.5 190 41 95 120 9.5 
 
 
 
 
 
 
 Controls 
S.  
No. AGE SEX Smoking Alcohol FH PH HT DM BMI TC HDL LDL TGL HOMOC
1 32 M Y N N N N N 20 136 42 70 133 6 
2 40 M N N N N N N 22 130 40 75 126 7.5 
3 35 M Y Y N N N N 21 152 39 64 132 6.8 
4 38 M N N N N N N 20.5 140 38 63 128 5.5 
5 42 F N N N N N N 21.6 160 40 92 115 6 
6 41 M N N N N N N 23.2 153 41 73 120 7.2 
7 43 F N N N N N N 20.9 145 45 72 132 7.7 
8 39 M Y Y N N N N 23 156 44 69 135 8.1 
9 38 M N N N N N N 22 166 41 68 140 6 
10 35 M N N N N N N 21 170 42 62 115 7 
11 39 M Y Y N N N N 24 192 39 72 122 8 
12 41 F N N N N N Y 25 183 42 97 140 11 
13 38 M N N N N Y N 23.6 178 43 90 135 12 
14 44 M Y N N N N Y 26 197 42 90 130 10 
15 40 M N N N N Y N 25.4 182 41 88 122 9.1 
16 43 M Y N N N N Y 24.8 189 38 85 111 11 
17 38 M N N N N N N 23.6 179 41 90 140 10.2 
18 33 F N N N N N Y 25.4 182 39 98 160 12.2 
19 40 M N N N N N Y 23.8 185 41 89 143 11.3 
20 42 M Y N N N N N 24.4 178 40 78 135 9.3 
21 41 F N N N N N N 25.5 190 38 95 145 12.2 
22 43 M N N N N N N 23.3 181 39 92 155 11.4 
23 36 M N N Y N N N 24 190 38 95 148 9 
24 39 M N N N N N N 24.8 178 39 87 130 8 
25 37 M Y N N N N N 25.2 176 38 88 132 7.8 
  
HT - HYPERTENSION HDL - HIGH DENSITY LIPOPROTEINS 
DM- DIABETES MELLITUS LDL- LOW DENSITY LIPOPROTEINS 
BMI- BODY MASS INDEX TG-TRIGLYCERIDES 
TC- TOTAL CHOLESTROL HOMOC-HOMOCYSTEINE 
PH - PAST HISTORY OF IHD FH- FAMILY HISTORY OF IHD 
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